These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 7532789)
1. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor. Elling CE; Nielsen SM; Schwartz TW Nature; 1995 Mar; 374(6517):74-7. PubMed ID: 7532789 [TBL] [Abstract][Full Text] [Related]
2. Connectivity and orientation of the seven helical bundle in the tachykinin NK-1 receptor probed by zinc site engineering. Elling CE; Schwartz TW EMBO J; 1996 Nov; 15(22):6213-9. PubMed ID: 8947044 [TBL] [Abstract][Full Text] [Related]
3. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. Rosenkilde MM; Cahir M; Gether U; Hjorth SA; Schwartz TW J Biol Chem; 1994 Nov; 269(45):28160-4. PubMed ID: 7525569 [TBL] [Abstract][Full Text] [Related]
4. The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human neurokinin-1 receptors. Jensen CJ; Gerard NP; Schwartz TW; Gether U Mol Pharmacol; 1994 Feb; 45(2):294-9. PubMed ID: 7509441 [TBL] [Abstract][Full Text] [Related]
6. Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. Holst B; Elling CE; Schwartz TW Mol Pharmacol; 2000 Aug; 58(2):263-70. PubMed ID: 10908293 [TBL] [Abstract][Full Text] [Related]
7. Conserved HisVI-17 of the NK-1 receptor is involved in binding of non-peptide antagonists but not substance P. Zoffmann S; Gether U; Schwartz TW FEBS Lett; 1993 Dec; 336(3):506-10. PubMed ID: 7506676 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. Cascieri MA; Macleod AM; Underwood D; Shiao LL; Ber E; Sadowski S; Yu H; Merchant KJ; Swain CJ; Strader CD J Biol Chem; 1994 Mar; 269(9):6587-91. PubMed ID: 7509807 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist. Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573 [TBL] [Abstract][Full Text] [Related]
10. The neurokinin-1 and neurokinin-2 receptor binding sites of MDL103,392 differ. Greenfeder S; Cheewatrakoolpong B; Billah M; Egan RW; Keene E; Murgolo NJ; Anthes JC Bioorg Med Chem; 1999 Dec; 7(12):2867-76. PubMed ID: 10658591 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists. Cascieri MA; Shiao LL; Mills SG; MacCoss M; Swain CJ; Yu H; Ber E; Sadowski S; Wu MT; Strader CD Mol Pharmacol; 1995 Apr; 47(4):660-5. PubMed ID: 7536886 [TBL] [Abstract][Full Text] [Related]
12. Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected]. Gether U; Nilsson L; Lowe JA; Schwartz TW J Biol Chem; 1994 Sep; 269(39):23959-64. PubMed ID: 7929043 [TBL] [Abstract][Full Text] [Related]
13. Construction of a high affinity zinc switch in the kappa-opioid receptor. Thirstrup K; Elling CE; Hjorth SA; Schwartz TW J Biol Chem; 1996 Apr; 271(14):7875-8. PubMed ID: 8626461 [TBL] [Abstract][Full Text] [Related]
14. Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor. Gether U; Emonds-Alt X; Brelière JC; Fujii T; Hagiwara D; Pradier L; Garret C; Johansen TE; Schwartz TW Mol Pharmacol; 1994 Mar; 45(3):500-8. PubMed ID: 8145735 [TBL] [Abstract][Full Text] [Related]
15. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide. Ciucci A; Palma C; Manzini S; Werge TM Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514 [TBL] [Abstract][Full Text] [Related]
16. Natural agonist enhancing bis-His zinc-site in transmembrane segment V of the tachykinin NK3 receptor. Rosenkilde MM; Lucibello M; Holst B; Schwartz TW FEBS Lett; 1998 Nov; 439(1-2):35-40. PubMed ID: 9849872 [TBL] [Abstract][Full Text] [Related]
17. The role of histidine 265 in antagonist binding to the neurokinin-1 receptor. Fong TM; Yu H; Cascieri MA; Underwood D; Swain CJ; Strader CD J Biol Chem; 1994 Jan; 269(4):2728-32. PubMed ID: 8300604 [TBL] [Abstract][Full Text] [Related]
18. Two related neurokinin-1 receptor antagonists have overlapping but different binding sites. Greenfeder S; Cheewatrakoolpong B; Anthes J; Billah M; Egan RW; Brown JE; Murgolo NJ Bioorg Med Chem; 1998 Feb; 6(2):189-94. PubMed ID: 9547942 [TBL] [Abstract][Full Text] [Related]
19. Photoaffinity labeling of mutant neurokinin-1 receptors reveals additional structural features of the substance P/NK-1 receptor complex. Macdonald D; Mierke DF; Li H; Pellegrini M; Sachais B; Krause JE; Leeman SE; Boyd ND Biochemistry; 2001 Feb; 40(8):2530-9. PubMed ID: 11327875 [TBL] [Abstract][Full Text] [Related]
20. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. Holst B; Zoffmann S; Elling CE; Hjorth SA; Schwartz TW Mol Pharmacol; 1998 Jan; 53(1):166-75. PubMed ID: 9443945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]